跳至主要内容
临床试验/NCT05014685
NCT05014685Unknown4 期

Proton Pump Inhibitor and Amoxicillin Combined Bismuth or Metronidazole for Helicobacter Pylori First-line Treatment: A Randomized Controlled Trial

Shanghai Zhongshan Hospital1 个研究点 分布在 1 个国家目标入组 732 人开始时间: 2021年8月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
732
试验地点
1
主要终点
Eradication rate of Helicobacter pylori

研究概览

简要总结

This randomized controlled clinical trial will identify the additional benefit of bismuth or metronidazole in proton pump inhibitor-amoxicillin-containing therapy for Helicobacter pylori first-line treatment. The completion of this trial will expand new therapy for the treatment of Helicobacter pylori, which can not only ensure clinical efficacy, but also reduce the use of antibiotics.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participate in the trial voluntarily, fully understand the trial, and sign the informed consent form (ICF).
  • 18-75 years old on the day of signing the ICF.
  • Helicobacter pylori infection confirmed by 13C-urea breath test or rapid urease test.
  • Have not received Helicobacter pylori eradication treatment before.

排除标准

  • Have received Hp eradication treatment.
  • Patients with severe heart, lung, kidney, liver, blood, nerve, endocrine, and psychiatric diseases.
  • Subjects or guardians refused to participate in the trial.
  • Alcohol and/or drugs Abuse (addiction or dependence) or poor compliance with doctor's judgment.
  • Have taken antibiotics, bismuth, PPI or Chinese traditional medicine 4 weeks before treatment.
  • Pregnant or lactating women.
  • Active peptic ulcer.
  • allergic to drugs used in the trial.
  • any other circumstances that are not suitable for recruitment.

研究组 & 干预措施

RA group

Experimental

干预措施: Rabeprazole (Drug)

RA group

Experimental

干预措施: Amoxicillin (Drug)

RAM group

Experimental

干预措施: Rabeprazole (Drug)

RAM group

Experimental

干预措施: Metronidazole (Drug)

RAM group

Experimental

干预措施: Amoxicillin (Drug)

RAB group

Experimental

干预措施: Rabeprazole (Drug)

RAB group

Experimental

干预措施: Bismuth potassium citrate (Drug)

RAB group

Experimental

干预措施: Amoxicillin (Drug)

RABM group

Active Comparator

干预措施: Rabeprazole (Drug)

RABM group

Active Comparator

干预措施: Bismuth potassium citrate (Drug)

RABM group

Active Comparator

干预措施: Metronidazole (Drug)

RABM group

Active Comparator

干预措施: Amoxicillin (Drug)

结局指标

主要结局

Eradication rate of Helicobacter pylori

时间窗: At least 4 weeks after completion of therapy

Eradication of Helicobacter pylori was defined as negative result of urea breath test (\<4‰ cut-off value).

次要结局

  • Eradication rate of Helicobacter pylori resistant strains(At least 4 weeks after completion of therapy)
  • Eradication rate of Helicobacter pylori susceptible strains(At least 4 weeks after completion of therapy)

研究者

发起方
Shanghai Zhongshan Hospital
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

PPI-amoxicillin for H. Pylori Treatment | 临床试验